Russell Tynes, MD
Internal Medicine · Shreveport, LANPI 1851323810
Payments from drug & device makers
Across 306 payments — averaging $26.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- Lilly USA, LLC$851
- Novo Nordisk$743
- AstraZeneca$689
- Amgen$618
- Pfizer$482
- plus $3K from 25 others
What the payments were for
- Consulting fees$1,20015%
- Travel & lodging$6057%
- Food & beverage$6,21377%
- Education$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $2,061 |
| Lilly USA, LLC | 42 | $851 |
| Novo Nordisk | 44 | $743 |
| AstraZeneca(2 entities) | 32 | $689 |
| Amgen | 23 | $618 |
| Pfizer | 25 | $482 |
| Lundbeck LLC | 18 | $336 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $326 |
| Johnson & Johnson | 2 | $210 |
| AbbVie(2 entities) | 11 | $189 |
| Sumitomo Pharma America, Inc. | 7 | $179 |
| Boehringer Ingelheim | 10 | $160 |
| Sanofi-aventis U.S. LLC | 11 | $156 |
| Amarin Pharma, Inc. | 3 | $155 |
| Merck | 8 | $140 |
| Bayer | 5 | $100 |
| Otsuka America Pharmaceutical, Inc. | 6 | $100 |
| Corium, LLC | 3 | $86 |
| Novartis | 4 | $77 |
| Biohaven Pharmaceuticals, Inc. | 2 | $58 |
| Currax Pharmaceuticals LLC | 3 | $55 |
| Exact Sciences | 3 | $50 |
| GSK | 3 | $45 |
| Astellas Pharma US Inc | 3 | $40 |
| Eisai Inc. | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Abbott | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,073 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 146 | $179,417 |
| RybelsusSemaglutide | 42 | $59,623 |
| TrulicityDulaglutide | 31 | $57,835 |
| OzempicSemaglutide | 35 | $46,471 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 36 | $45,189 |
| JardianceEmpagliflozin | 44 | $44,735 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $42,017 |
| EliquisApixaban | 40 | $41,688 |
| Repatha SureclickEvolocumab | 41 | $39,497 |
| XareltoRivaroxaban | 21 | $27,758 |
| MyrbetriqMirabegron | 25 | $24,962 |
| Xigduo XrDapaglifloz Propaned/Metformin | 33 | $24,771 |
| TrintellixVortioxetine Hydrobromide | 14 | $13,213 |
| FarxigaDapagliflozin Propanediol | 12 | $12,082 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $9,366 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $851 | $237,252177 claims |
| Novo NordiskRybelsus, Ozempic | $743 | $106,09577 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $156 | $45,18936 claims |
| Boehringer IngelheimJardiance | $160 | $44,73544 claims |
| PfizerEliquis | $482 | $41,68840 claims |
| Johnson & JohnsonXarelto | $210 | $27,75821 claims |
| Astellas Pharma US IncMyrbetriq | $40 | $24,96225 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $689 | $21,44925 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $326 | $13,21314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Shreveport
- Deepika RallaShreveport$261K
- Maliha AgloriaShreveport$181K
- Bharat SachdevaShreveport$165K
- Rajan KhannaShreveport$59K
- Ishak MansiShreveport$53K
- Wendell WallShreveport$25K
- Attila BaloghShreveport$18K
- Ammar AlqaidShreveport$18K
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.